BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share

 
• By Alaric DeArment
  
BridgeBio announced positive topline results from the PROPEL 3 trial of infigratinib in achondroplasia (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip